Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan R Emberson

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Medrxiv : the Preprint Server for Health Sciences|May 3, 2024
Prediabetes as a risk factor for all-cause and cause-specific mortality: a prospective analysis of 115,919 adults without diabetes in Mexico CityCarlos A Fermín-Martínez, Omar Yaxmehen Bello-Chavolla, César Daniel Paz-Cabrera, et al.
Nature Communications|January 31, 2024
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Peter W Horby, Leon Peto, et al.
BMJ (Clinical Research Ed.)|August 30, 2019
RoB 2: a revised tool for assessing risk of bias in randomised trialsJonathan A C Sterne, Jelena Savović, Matthew J Page, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 13, 2025
Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic SubstudyDoreen Zhu, Parminder K Judge, Susan T Francis, et al.
The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Type 2 diabetes genetics in 125,000 admixed adults from Mexico CityJason M Torres, Jaime Berumen, Diego Aguilar-Ramirez, et al.
Nature|February 8, 2024
Author Correction: Genotyping, sequencing and analysis of 140,000 adults from Mexico CityAndrey Ziyatdinov, Jason Torres, Jesús Alegre-Díaz, et al.
Nature|October 11, 2023
Genotyping, sequencing and analysis of 140,000 adults from Mexico CityAndrey Ziyatdinov, Jason Torres, Jesús Alegre-Díaz, et al.
Nature Communications|August 23, 2022
Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetesParsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Medrxiv : the Preprint Server for Health Sciences|May 3, 2024
Prediabetes as a risk factor for all-cause and cause-specific mortality: a prospective analysis of 115,919 adults without diabetes in Mexico CityCarlos A Fermín-Martínez, Omar Yaxmehen Bello-Chavolla, César Daniel Paz-Cabrera, et al.
Nature Communications|January 31, 2024
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Peter W Horby, Leon Peto, et al.
BMJ (Clinical Research Ed.)|August 30, 2019
RoB 2: a revised tool for assessing risk of bias in randomised trialsJonathan A C Sterne, Jelena Savović, Matthew J Page, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 13, 2025
Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic SubstudyDoreen Zhu, Parminder K Judge, Susan T Francis, et al.
The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Type 2 diabetes genetics in 125,000 admixed adults from Mexico CityJason M Torres, Jaime Berumen, Diego Aguilar-Ramirez, et al.
Nature|February 8, 2024
Author Correction: Genotyping, sequencing and analysis of 140,000 adults from Mexico CityAndrey Ziyatdinov, Jason Torres, Jesús Alegre-Díaz, et al.
Nature|October 11, 2023
Genotyping, sequencing and analysis of 140,000 adults from Mexico CityAndrey Ziyatdinov, Jason Torres, Jesús Alegre-Díaz, et al.
Nature Communications|August 23, 2022
Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetesParsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al.
Pageof 8